Working… Menu

REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02565719
Recruitment Status : Completed
First Posted : October 1, 2015
Last Update Posted : September 10, 2019
Information provided by (Responsible Party):
Replicor Inc.